Company Profile

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Latest News

Cytokinetics to Announce Second Quarter Results on August 6, 2026

GlobeNewswire • 07/23/2026

Cytokinetics Insider Sold Shares Worth $282,065, According to a Recent SEC Filing

MT Newswires • 07/23/2026

IBD Live Q&A Summary, Stock Lists For Thursday, July 23, 2026

Investor's Business Daily • 07/23/2026

Cytokinetics CEO on the launch of its first commercial drug

Yahoo Finance Video • 07/21/2026

Are Medical Stocks Lagging Concentra Group Holdings Parent, Inc. (CON) This Year?

Zacks • 07/20/2026